Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    BK1310-J03
Previous Study | Return to List | Next Study

Confirmatory Study of BK1310 in Healthy Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03891758
Recruitment Status : Active, not recruiting
First Posted : March 27, 2019
Last Update Posted : June 7, 2019
Sponsor:
Collaborator:
The Research Foundation for Microbial Diseases of Osaka University
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Corporation

Brief Summary:
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with co-administration of ActHIB® and Tetrabik, as well as efficacy and safety, in healthy infants.

Condition or disease Intervention/treatment Phase
Tetanus Diphtheria Pertussis Poliomyelitis Bacterial Meningitis Biological: DPT-IPV-Hib Biological: Hib vaccine Biological: DPT-IPV Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase 3 Study of BK1310 Compared With ActHIB® and Tetrabik in Healthy Infants: A Randomized, Assessor-blind, Active-controlled
Actual Study Start Date : April 1, 2019
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2020


Arm Intervention/treatment
Experimental: BK1310 Biological: DPT-IPV-Hib
0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Other Name: BK1310

Active Comparator: ActHIB® and Tetrabik Biological: Hib vaccine
0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Other Name: ActHIB®

Biological: DPT-IPV
0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Other Name: Tetrabik




Primary Outcome Measures :
  1. Antibody prevalence rate against anti-PRP with 1 μg/mL or higher, diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4 weeks after the primary immunization (Visit 4) ]

Secondary Outcome Measures :
  1. Anti-PRP antibody prevalence rate with 0.15 μg/mL or higher [ Time Frame: 4weeks after the primary immunization (Visit 4) ]
  2. Geometric mean antibody titer of anti-PRP antibody [ Time Frame: 4weeks after the primary immunization (Visit 4) ]
  3. Anti-PRP antibody prevalence rate with 1 μg/mL or higher [ Time Frame: 4weeks after the booster dose (Visit 6) ]
  4. Geometric mean antibody titer of anti-PRP antibody [ Time Frame: 4weeks after the booster dose (Visit 6) ]
  5. Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4weeks after the primary immunization (Visit 4) ]
  6. Antibody prevalence rate against diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4weeks after the booster dose (Visit 6) ]
  7. Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus [ Time Frame: 4weeks after the booster dose (Visit 6) ]
  8. Adverse events and adverse reactions [ Time Frame: Through study completion, an average of 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 42 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy infants aged ≥2 and <43 months at the first vaccination of the study drug (recommended: ≥2 and <7 months)
  • Written informed consent is obtained from a legal guardian (parent)

Exclusion Criteria:

  • Possibility of anaphylaxis due to food or pharmaceuticals
  • With experience of Hib infection, diphtheria, pertussis, tetanus or acute poliomyelitis
  • With experience of Hib, diphteria, pertussis, tetanus or polio vaccination.
  • Participated in other studies within 12 weeks before obtaining consent
  • Considered to be not eligible by the principal investigators (sub-investigators) of the enrollment

Additional screening criteria check may apply for qualification.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03891758


Locations
Layout table for location information
Japan
Investigational Site
Fukuoka-shi, Fukuoka, Japan
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
The Research Foundation for Microbial Diseases of Osaka University
Investigators
Layout table for investigator information
Study Director: General Manager Mitsubishi Tanabe Pharma Corporation

Layout table for additonal information
Responsible Party: Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier: NCT03891758     History of Changes
Other Study ID Numbers: BK1310-J03
First Posted: March 27, 2019    Key Record Dates
Last Update Posted: June 7, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Haemophilus influenza type b
Adsorbed Diphtheria-purified Pertussis-Tetanus- Inactivate poliovirus combined vaccine
Hib
DPT-IPV

Additional relevant MeSH terms:
Layout table for MeSH terms
Meningitis
Whooping Cough
Tetanus
Diphtheria
Poliomyelitis
Meningitis, Bacterial
Central Nervous System Diseases
Nervous System Diseases
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Clostridium Infections
Gram-Positive Bacterial Infections
Corynebacterium Infections
Actinomycetales Infections
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Myelitis
Central Nervous System Infections
Spinal Cord Diseases
Neuromuscular Diseases
Central Nervous System Bacterial Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs